Objective: Prohepcidin (Pro-Hep), synthesized in the liver, is the prohormone of hepcidin (Hep), which reduces iron absorption in the gut; its synthesis is enhanced by inflammation and is reduced during hypoxia. We aimed to study the hypothesis that infants born small for gestational age (SGA) have reduced cord blood concentrations of Pro-Hep.
Objective: Prohepcidin (Pro-Hep), synthesized in the liver, is the prohormone of hepcidin (Hep), which reduces iron absorption in the gut; its synthesis is enhanced by inflammation and is reduced during hypoxia. We aimed to study the hypothesis that infants born small for gestational age (SGA) have reduced cord blood concentrations of Pro-Hep.
Study Design: Cord blood was collected from 20 SGA (term and near term >35 week gestation) infants and 20 appropriate for gestational age (AGA) controls. We excluded infants exposed to maternal chronic diseases, smoking, diabetes, alcohol or drug use. Both groups had a 1 min Apgar score above or equal to 7 and had normal cord blood pH (above 7.25). ELISA was used to determine serum concentrations of Pro-Hep and erythropoietin (EPO). Circulating CD71 þ /CD45 À /SSC low cells were measured by flow cytometry as an index of erythroid progenitors.
Result: There were no significant differences between groups in terms of hemoglobin concentrations, and Pro-Hep. In contrast, EPO levels and circulating CD71 þ /CD45 À /SSC low erythroid progenitors were significantly higher in the SGA group. These differences remained significant even after controlling for gestational age and gravidity.
Introduction Prohepcidin (Pro-Hep) is a liver produced hormone whose posttranscriptional transformation into hepcidin (Hep) leads primarily to a reduction in iron absorption in the gut; 1 the production of Hep is enhanced by inflammation, and it seems to have a significant function in other various conditions such as iron export from macrophages and hepatocytes anemia of chronic diseases and resistance to erythropoietin (EPO). 2, 3 Hep production has also been shown to be reduced during anemia and hypoxia and is also affected, to a minor degree, by serum iron levels. 2 Little is known about the liver production of Pro-Hep, its role and regulation during the intrauterine life. 4, 5 Intrauterine growth restriction (IUGR) creates an adverse intrauterine environment to the fetus, to the inclusion of relative oxygen deprivation. In support of this are the facts that fetal hypoxia has been documented in IUGR fetuses by cordocentesis; 6 that EPO is elevated in newborn small for gestational age (SGA) infants (presumably in response to fetal hypoxia), 7 and IUGR is a known risk factor for increased erythropoiesis, as evidenced by increased numbers of circulating nucleated red blood cells at birth 8 and increased rates of polycythemia. 9 We therefore conducted this prospective study to test the hypothesis that cord blood of SGA neonates has higher circulating EPO, lower circulating Pro-Hep and higher circulating erythroid progenitors than cord blood of appropriate for gestational age (AGA) neonates.
Methods

Patients
In this pilot study, cord blood samples were collected from 20 SGA (term and near term >35 weeks gestation) infants and 20 AGA controls. The infants were defined as SGA or AGA using our own Israeli curves published by one of us. 10 Cord blood was obtained from puncture of the umbilical vein in a double clamped segment of the cord. To obtain a relatively homogenous group of infants (in terms of the etiology of the presumed fetal growth restriction), we excluded infants exposed to maternal chronic diseases, smoking, diabetes, alcohol or drug use. We also excluded all infants with neonatal depression (both groups had to have Apgar score above or equal to 7 at 1 min and a normal cord pH >7.25), patient with congenital malformations, intrauterine infections and genetic syndromes associated with IUGR. The patients were consecutive and the study was approved by our local ethics committee. Written informed consent forms were signed by both parents of the child.
Laboratory methods
Pro-Hep was measured using ELISA (DRG Diagnostics, Marburg, Germany); EPO was also measured by ELISA (R&D Systems Europe Ltd, Abingdon, UK). Circulating CD71 þ /CD45 À /SSC low cells were measured by flow cytometry as an index of erythroid progenitors. 
Results
The clinical characteristics of the patients in both groups are presented in Table 1 . Briefly, the patients were similar in terms of maternal age, parity, mode of analgesia (epidural or spinal in all cases), mode of delivery, race (all Jewish caucasians), infant gender and Apgar scores. Groups differed significantly in terms of gravidity, gestational age, birth weight and head circumference (Table 1) .
In univariate analysis, there were no significant differences between SGA and AGA neonates in terms of hemoglobin concentrations (16.3±1.6 versus 15.2±2.3, P ¼ 0.132), and ProHep (104 ± 18 versus 99 ± 22, P ¼ 0.22; Table 2 ). In contrast, there was a significant difference in EPO concentrations (34 (14 to 263) versus 22 (9 to 168), P<0.05) and CD71 þ /CD45 À /SSC low erythroid progenitor cells concentrations (1.13 (0.12 to 7.9) versus 0.3 (0.04 to 1.24), P<0.001) that were significantly higher in the SGA group than the AGA control group (Table 2) . In multiple regression analysis, the significant differences between groups in CD71 þ /CD45 À /SSC low values or in ranked EPO values remained significant even after taking into account gestational age and gravidity.
Discussion
We have shown that SGA infants have evidence of increased fetal erythropoiesis, as determined by increased cord blood EPO concentrations and increased circulating erythroid progenitors. Although increased circulating normoblast counts in SGA infants has been reported by us 8 and others, 12 to the best of our knowledge, this is the first study that used high definition flow cytometry to also show the evidence of elevated erythrocyte precursors in IUGR. We thus speculate that relative fetal hypoxia in the SGA group led to increased EPO production, which in turns stimulated erythropoiesis.
We also found that, contrary to EPO upregulation during IUGR, Pro-Hep concentration was not significantly affected by IUGR. If we assume that this lack of difference is real, we can only speculate about it. A theoretical possible explanation is that though fetal renal hypoxia in IUGR leads to EPO production, there might be no sufficient liver hypoxia to downregulate Pro-Hep production. Indeed, the fetal kidney gets its oxygenated blood supply from the descending aorta, which itself gets it from the left ventricle, after a certain degree of mixing of maximally oxygenated blood (originating from the umbilical vein) with deoxygenated blood (coming from the superior and inferior vena cava in the right atrium), with additional mixing at the level of the patent foramen ovale and the ductus arteriosus. 13 In contrast, the liver receives its oxygenated blood supply directly from the umbilical vein and before any mixing. Subsequently, measured oxygen saturation in the fetal umbilical vein is approximately 85%, whereas in the descending aorta it is only approximately 60%. 13 In this study, it was important to measure Pro-Hep (directly produced by hepatocytes), rather than Hep, which is the posttranscriptional product of Pro-Hep, and may be regulated differently. Indeed Hep serum concentrations do not correlate well with Pro-Hep concentrations, and reflect both posttranscriptional modifications One limitation of our study is that in virtue of its pilot nature, it may have been underpowered (with a sample size of only 20 per group) to enable the detection of a significant difference between groups in terms of Pro-Hep concentrations. Indeed, power calculation with such a sample size gives us the likelihood of a type 2 error (the probability of not detecting a true difference) of 0.84, that is a power of 0.16. To differentiate between 104 1 (in the IUGR group) and 99 pg ml À1 (in the control group) to be significant at a P-value of 0.05 and a power of 0.8, we would have needed a sample size of 161 patients in each group. We believe however that the risk of a type 2 error in our case is relatively unimportant because, first of all, the difference, if any, between the two groups is minimal (4%), and second the difference seen, if any, was opposite to the hypothesis of reduction of circulating ProHep by hypoxia.
In summary, we conclude that infants delivered SGA have evidence of increased erythropoiesis, presumably because of hypoxia-induced EPO production. We speculate that, contrary to EPO upregulation during IUGR, Pro-Hep concentration appears not to be affected by IUGR.
